TScan Therapeutics (NASDAQ:TCRX) Price Target Cut to $6.00 by Analysts at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX) had its target price reduced by Needham & Company LLC from $9.00 to $6.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also issued reports about the company. Wall Street Zen raised TScan Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Finally, Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, TScan Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.20.

TScan Therapeutics Price Performance

TCRX opened at $1.12 on Tuesday. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $6.23. The company has a 50 day moving average of $1.95 and a two-hundred day moving average of $1.73. The company has a market cap of $63.56 million, a P/E ratio of -1.03 and a beta of 1.00. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. On average, analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd acquired a new stake in shares of TScan Therapeutics during the second quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in TScan Therapeutics in the second quarter valued at $29,000. Quadrature Capital Ltd acquired a new position in TScan Therapeutics during the 2nd quarter worth $33,000. Boothbay Fund Management LLC grew its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of TScan Therapeutics in the 1st quarter worth about $49,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.